Oxurion Eyes $12bn Opportunity After Restructuring
New CEO Completes Strategic Review
The Belgium-headquartered group is pulling the plug on its dry AMD research efforts and investments in cancer venture Oncurious to focus on two early-stage compounds that show promise for diabetic macular edema and other retinal diseases.
You may also be interested in...
Oxurion Pins Hopes On THR-149 After THR-687 Flops In DME
THR-687’s failure in Phase II marks the second drug to flunk in the disease after a Phase IIa study of THR-317 showed disappointing results in 2019, but THR-149 has shown some encouraging data.
Oxurion's Anti-PIGF Antibody Disappoints in Diabetic Macular Edema
The primary endpoint was missed in a Phase IIa study of Oxurion’s THR-317 in diabetic macular edema, but vision did improve in two patient subgroups.
Roche Continues To Cast Its Collaborations Net Wide
The Swiss major gets around 3,000 proposals per year and has assembled a 120-strong team to sift through them and access the best science out there. Global head of pharma partnering James Sabry tells Scrip what Roche is looking for in a partner.